ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average - Should You Sell?

Key Points

• ProQR Therapeutics' stock price has recently surpassed its 50-day moving average at $2.07, trading as high as $2.15 before closing at $2.06.
• Wall Street analysts maintain a generally positive outlook for ProQR Therapeutics, with an average target price of $8.00 and most ratings being "buy" or "outperform."
• ProQR reported a loss of $0.11 earnings per share in its latest quarterly earnings, slightly missing analyst expectations, with projected earnings for the current year at -$0.31 per share.

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report)'s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.07 and traded as high as $2.15. ProQR Therapeutics shares last traded at $2.06, with a volume of 117,443 shares trading hands.

Analyst Ratings Changes

Several analysts have recently weighed in on PRQR shares. Cantor Fitzgerald restated an "overweight" rating and set a $8.00 price target on shares of ProQR Therapeutics in a report on Friday, June 27th. JMP Securities reissued a "market outperform" rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research report on Friday, June 27th. Chardan Capital reiterated a "buy" rating and set a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday. Oppenheimer lowered their price target on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Finally, Evercore ISI reissued an "outperform" rating on shares of ProQR Therapeutics in a report on Friday, July 11th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

ProQR Therapeutics Price Performance

The stock has a market capitalization of $207.79 million, a price-to-earnings ratio of -4.29 and a beta of 0.43. The business has a fifty day moving average of $2.09 and a 200 day moving average of $1.88.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). The firm had revenue of $4.33 million for the quarter, compared to analyst estimates of $5.01 million. ProQR Therapeutics had a negative return on equity of 61.25% and a negative net margin of 238.52%. On average, equities research analysts expect that ProQR Therapeutics N.V. will post -0.31 EPS for the current year.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRQR. Vontobel Holding Ltd. lifted its stake in shares of ProQR Therapeutics by 76.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 63,979 shares of the biopharmaceutical company's stock worth $131,000 after acquiring an additional 27,722 shares during the period. Jane Street Group LLC lifted its holdings in ProQR Therapeutics by 699.3% during the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company's stock valued at $121,000 after purchasing an additional 79,720 shares during the last quarter. Affinity Asset Advisors LLC grew its position in shares of ProQR Therapeutics by 16.3% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company's stock worth $4,368,000 after buying an additional 459,512 shares during the period. Walleye Capital LLC lifted its position in shares of ProQR Therapeutics by 11.6% in the first quarter. Walleye Capital LLC now owns 503,564 shares of the biopharmaceutical company's stock worth $670,000 after purchasing an additional 52,261 shares in the last quarter. Finally, Aberdeen Group plc acquired a new position in shares of ProQR Therapeutics in the first quarter valued at $2,461,000. Hedge funds and other institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).